Physician profile
Alan Tong
NPI 1770215154
$16,311.00
in general payments reported to CMS, 2019-2025
28 companies · $4,578 in 2025
The $4,578 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,361 · 2023: $4,552 · 2024: $4,820 · 2025: $4,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,007.58 |
| Education | $942.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,650.96 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,209.57 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,945.20 | 2022-2025 | |
| Janssen Biotech, INC. | $1,641.83 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $1,228.70 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $980.44 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $946.27 | 2022-2025 | |
| Galderma Laboratories, L.P. | $767.27 | 2022-2025 | Nemluvio, Twyneo, Aklief |
| E.R. Squibb & Sons, L.L.C. | $745.68 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $633.01 | 2022-2024 | Winlevi, Absorica Ld, Ilumya |
| Arcutis Biotherapeutics, INC. | $484.26 | 2023-2024 | Zoryve |
| Pfizer INC. | $439.35 | 2022-2025 | |
| Ucb, INC. | $295.24 | 2022-2025 | Bimzelx |
| Organon LLC | $250.26 | 2025 | Vtama, Nexplanon |
| Dermavant Sciences, INC. | $184.16 | 2023-2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $169.42 | 2023-2025 | Adbry, Anzupgo |
| Amgen INC. | $154.59 | 2022-2024 | Otezla |
| Janssen Scientific Affairs, LLC | $148.78 | 2022 | |
| Merz North America, INC. | $113.27 | 2022-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.55 | 2023-2025 | Jublia, Cabtreo, Arazlo |
| Genentech USA, INC. | $69.04 | 2023-2024 | Xolair |
| Almirall LLC | $31.86 | 2023 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.93 | 2022 | |
| Cipher Pharmaceuticals US LLC | $21.83 | 2025 | Spinosad, Natroba |
| Paratek Pharmaceuticals, INC. | $21.49 | 2025 | Nuzyra |
| Icad, INC | $19.44 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $19.28 | 2023 | Valchlor |
| Nobelpharma America, LLC | $13.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Tong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.